HealthQuill Clinical trials
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.
Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

Read More
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, according to a company statement.
Drugs Health Pharma

EMA approves Sanofi’s treatment for obstructive pulmonary disease

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.

Read More
In a bid to include an under-represented population, the US drug regulator has advised healthcare firms to improve racial, ethnic and other diversity factors during clinical trials.
Drugs Health Pharma

USFDA issues new draft guidance for trials to expand race, ethnicity

In a bid to include an under-represented population, the US drug regulator has advised healthcare firms to improve racial, ethnic and other diversity.

Read More
Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.
Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients 

Tirzepatide, an obesity drug of  Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

Read More
AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.
Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Read More
Takeda Pharmaceutical Company’s two trials for treating epilepsy did not meet its primary goals of seizure frequency, the Japanese company announced.
Drugs Health Pharma

Takeda’s trials for epilepsy treatment fail to meet primary seizure goals

Takeda Pharmaceutical Company’s two trials for treating epilepsy did not meet its primary goals of seizure frequency, the Japanese company announced.

Read More
he US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria that cause invasive pneumococcal disease.
Drugs Health Pharma

Merck’s vaccine for pneumococcal disease gets FDA’s green light

The US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria.

Read More
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
Drugs Health Pharma

FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer

The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.

Read More
AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company statement.
Drugs Health Pharma

AstraZeneca’s trial drug for mantle cell lymphoma raises survival rate

AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.

Read More
Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to a statement.
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More